Daphne Foust1, Shazia Tabassum Hakim2 and Joseph Angel de Soto2*
1Foust Medical Clinic, Paris, France
2School of Science, Technology, Engineering and Math, Dine College, Arizona, USA
*Corresponding Author: Joseph Angel de Soto, School of Science, Technology, Engineering and Math, Dine College, Arizona, USA.
Received: September 07, 2020; Published: October , 2020
Background: The COVID-19 outbreak has led to a world-wide pandemic that has infected over two million people and caused over one hundred thousand deaths. The virus first discovered in Wuhan China in Dec. 2019, seems to have originated either in the United States or the Guangdong province as early as September 2019. Infection by SARs-CoV-2 virus can lead to pneumonia and adult respiratory distress syndrome (ARDS) which is the leading cause of morbidity and mortality for this disease.
Objective: This review focuses on the mechanism of action of a representative sampling of some of the most promising pharmacological approaches to treating COVID-19 based pneumonia and the related cytokine storm.
Results: The current medications showing promise either focus in interfering with the viral life cycle or interfering with the cytokine storm that leads from pneumonia to ARDs.
Conclusion: Developing therapeutics interfering with the viral lifecycle, modulating the cytokine storm and protecting the end organs show promise in significantly reducing the morbidity and mortality of COVID-19.
Keywords: Covid-19; Therapeutics; Antiviral; Cytokine Storm; Therapy; Treatment; Pharmacological; SAR-CoV-2
Citation: Joseph Angel de Soto., et al. “Complementary Pharmacological Treatment and Therapeutic Prospects for COVID-19". Acta Scientific Pharmaceutical Sciences 4.11 (2020): .
Copyright: © 2020 Joseph Angel de Soto., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.